Syndax Pharmaceuticals (SNDX) Net Cash Flow (2015 - 2026)

Syndax Pharmaceuticals' Net Cash Flow history runs 12 years deep, the most recent figure standing at -$4.0 million for Q1 2026.

• On a quarterly basis, Net Cash Flow fell 4385.56% year-over-year to -$4.0 million in Q1 2026; TTM through Mar 2026 was -$23.2 million, a 158.95% decrease from a year earlier, with the FY2025 full-year figure at -$19.3 million, up 86.36% from the prior year.
• Net Cash Flow slipped to -$4.0 million in Q1 2026 per SNDX's latest filing, from $18.0 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $200.8 million in Q4 2023 and bottomed at -$180.8 million in Q1 2024.
• The 5-year median for Net Cash Flow is -$2.7 million (2023), against an average of -$5.4 million.
• Across the five-year window, Net Cash Flow jumped 6641.99% in 2023 and plunged 4385.56% in 2026, its largest moves.
• Year by year, Net Cash Flow stood at $3.0 million in 2022, then soared by 6641.99% to $200.8 million in 2023, then slumped by 89.51% to $21.1 million in 2024, then fell by 14.51% to $18.0 million in 2025, then slumped by 122.42% to -$4.0 million in 2026.
• Per Business Quant, the three latest SNDX Net Cash Flow figures stand at -$4.0 million (Q1 2026), $18.0 million (Q4 2025), and $8.2 million (Q3 2025).